PRESS RELEASE published on 06/27/2024 at 07:00, 4 months 24 days ago SCHOTT Pharma continues growth path in the second quarter of fiscal year 2024 SCHOTT Pharma reports 11% revenue growth in Q2 2024, reaffirms guidance for fiscal year. Focus on high-value solutions and expansion. Key figures and strategic developments outlined Financial Results Expansion Revenue Growth SCHOTT Pharma High-value Solutions
BRIEF published on 06/14/2024 at 13:03, 5 months 7 days ago SCHOTT Pharma ouvre une usine de production de pointe en Hongrie SCHOTT Pharma Usine Hongrie Seringues En Verre Tendances Pharmaceutiques
BRIEF published on 06/14/2024 at 13:03, 5 months 7 days ago SCHOTT Pharma Opens State-of-the-Art Production Facility in Hungary SCHOTT Pharma Pharmaceutical Trends Hungary Production Facility Glass Syringes
PRESS RELEASE published on 06/14/2024 at 12:58, 5 months 7 days ago Expanding prefillable glass syringe output: SCHOTT Pharma opens state-of-the-art production facility in Lukácsháza, Hungary SCHOTT Pharma opens new production facility in Hungary, expanding prefillable glass syringe output to support pharma market growth and trends SCHOTT Pharma Pharma Industry Hungary Production Facility Prefillable Glass Syringes
BRIEF published on 05/14/2024 at 18:24, 6 months 6 days ago SCHOTT Pharma Reaffirms FY 24 Outlook, Anticipates Slower Growth in FY 25 Due to Reduced Syringe Demand Financial Results SCHOTT Pharma FY 24 Forecast FY 25 Growth Impact Syringe Demand Decrease
BRIEF published on 05/14/2024 at 18:24, 6 months 6 days ago SCHOTT Pharma réaffirme ses perspectives pour l’exercice 24 et prévoit un ralentissement de la croissance au cours de l’exercice 25 en raison de la réduction de la demande de seringues Résultats Financiers SCHOTT Pharma Prévisions Pour L'exercice 24 Impact Sur La Croissance Pour L’exercice 25 Diminution De La Demande En Seringues
PRESS RELEASE published on 05/14/2024 at 18:19, 6 months 6 days ago SCHOTT Pharma confirms outlook for FY 24 based on Q2 results; FY 25 impacted by slower growth from syringes SCHOTT Pharma confirms FY 24 outlook based on Q2 results; FY 25 impacted by slower growth from syringes. H1 24 revenues up 9% at constant currencies Revenue Growth SCHOTT Pharma Syringes FY 24 FY 25
BRIEF published on 05/14/2024 at 18:08, 6 months 6 days ago SCHOTT Pharma anticipe l’impact du ralentissement des ventes de seringues sur l’exercice 2025 SCHOTT Pharma Marge D'EBITDA Hausse Des Revenus Exercice 2025 Demande De Seringues
BRIEF published on 05/14/2024 at 18:08, 6 months 6 days ago SCHOTT Pharma Anticipates Fiscal Year 2025 Impact Due to Slower Syringe Sales Revenue Growth EBITDA Margin SCHOTT Pharma Fiscal Year 2025 Syringe Demand
PRESS RELEASE published on 05/14/2024 at 18:03, 6 months 6 days ago EQS-Adhoc: SCHOTT Pharma AG & Co. KGaA: SCHOTT Pharma see FY 25 impacted by slower growth from syringes SCHOTT Pharma AG & Co. KGaA expects slower revenue growth in FY 2024/2025 due to decreased demand for syringes from a major customer, impacting EBITDA margin expansion Revenue Growth EBITDA Margin SCHOTT Pharma AG & Co. KGaA FY 2024/2025 Syringes
Published on 11/21/2024 at 15:30, 33 minutes ago CLS Health Opens New Comprehensive Care Clinic in Sugar Creek
Published on 11/21/2024 at 15:05, 58 minutes ago "The Not-So-Secret Lives of REAL 'Mormon' Wives" - the Eye-Opening New Book From Cedar Fort Publishing & Media - is Now Available for Purchase, Just in Time for Christmas
Published on 11/21/2024 at 15:00, 1 hour 3 minutes ago 2-10 Home Buyers Warranty Makes Triumphant Entry Into Oklahoma Market
Published on 11/21/2024 at 15:00, 1 hour 3 minutes ago Sound Physicians’ ACO Achieves $22.9M Total Savings in 2023 Medicare Shared Savings Program
Published on 11/21/2024 at 15:00, 1 hour 3 minutes ago BlackBerry AtHoc "In Process" Finalization for FedRAMP High Authorization
Published on 11/21/2024 at 15:24, 39 minutes ago Form 8.3 - The Vanguard Group, Inc.: International Paper Company
Published on 11/21/2024 at 15:22, 41 minutes ago Form 8.3 - The Vanguard Group, Inc.: TI Fluid Systems plc
Published on 11/21/2024 at 15:20, 42 minutes ago Form 8.3 - The Vanguard Group, Inc.: AngloGold Ashanti plc
Published on 11/21/2024 at 06:58, 9 hours 5 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 9 hours 5 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 9 hours 5 minutes ago Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 19 hours 56 minutes ago Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 20 hours 43 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
